- Home
- NCPL vs ADXN Comparison
NCPL vs ADXN Comparison
Compare NCPL & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- ADXN
- Stock Information
- Founded
- NCPL 1984
- ADXN 2002
- Country
- NCPL United States
- ADXN Switzerland
- Employees
- NCPL N/A
- ADXN N/A
- Industry
- NCPL Investment Managers
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- ADXN Health Care
- Exchange
- NCPL Nasdaq
- ADXN Nasdaq
- Market Cap
- NCPL 9.1M
- ADXN 8.5M
- IPO Year
- NCPL N/A
- ADXN N/A
- Fundamental
- Price
- NCPL $1.99
- ADXN $9.47
- Analyst Decision
- NCPL
- ADXN
- Analyst Count
- NCPL 0
- ADXN 0
- Target Price
- NCPL N/A
- ADXN N/A
- AVG Volume (30 Days)
- NCPL 69.9K
- ADXN 24.2K
- Earning Date
- NCPL 12-15-2025
- ADXN 11-21-2025
- Dividend Yield
- NCPL N/A
- ADXN N/A
- EPS Growth
- NCPL N/A
- ADXN N/A
- EPS
- NCPL N/A
- ADXN N/A
- Revenue
- NCPL $917,291.00
- ADXN $210,347.00
- Revenue This Year
- NCPL $739.37
- ADXN $86.57
- Revenue Next Year
- NCPL N/A
- ADXN N/A
- P/E Ratio
- NCPL N/A
- ADXN N/A
- Revenue Growth
- NCPL N/A
- ADXN N/A
- 52 Week Low
- NCPL $1.42
- ADXN $6.51
- 52 Week High
- NCPL $8.75
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- NCPL 42.61
- ADXN 51.88
- Support Level
- NCPL $2.20
- ADXN $9.01
- Resistance Level
- NCPL $2.53
- ADXN $9.98
- Average True Range (ATR)
- NCPL 0.14
- ADXN 0.79
- MACD
- NCPL -0.01
- ADXN 0.03
- Stochastic Oscillator
- NCPL 5.23
- ADXN 27.25
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.